Bandwidth Inc vs Mesoblast Limited — how do they compare? Bandwidth Inc trades at $53.96 (market cap $1.67B), while Mesoblast Limited trades at $15.7 (market cap $2.20B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Bandwidth Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| BAND | MESO | |
|---|---|---|
Market Cap | $1.67B | $2.20B |
Sector | Technology | Technology |
52-Week High | $78.44 | $20.96 |
52-Week Low | $12.82 | $12.88 |
Enterprise Value | $2.05B | $2.20B |
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $51.97, up 0.68% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with 22% revenue growth and raised full-year guidance, though profitability remains thin with a 0.27% net margin. Analyst sentiment is overwhelmingly positive with a $80.33 consensus price target representing 55% upside potential.
The outlook is promising given accelerating AI-driven communications demand and enterprise wins, but investors face valuation concerns with elevated EV/EBITDA of 34.27. Key risks include execution on growth targets and competitive pressures in the cloud communications space. The stock's recent 21.7% weekly gain suggests momentum but warrants caution near technical resistance.
MESO trades at $16.78, down 0.83% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong revenue growth with Ryoncil generating $115 million in its first full year, though it remains unprofitable with a -144.33% net income margin. Recent developments include achieving Phase 3 trial targets for chronic back pain and securing a $50 million non-dilutive facility.
MESO presents a high-risk, high-reward opportunity with significant commercial traction but persistent losses. The bullish analyst consensus and recent regulatory progress support upside potential, though profitability concerns and high P/S ratio of 30.52 warrant caution for risk-averse investors.
Trailing returns across standard periods
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →